Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | How age as a prognostic factor affects treatment options for ALL

Oliver Ottmann • 3 Jun 2020
ESH AL 2020
Acute Lymphoblastic Leukemia Leukemia

Age is a prevalent prognostic factor to take into consideration when choosing acute lymphoblastic leukemia (ALL) treatment. Oliver Ottmann, MD, FRCPath, University of Cardiff, Cardiff, UK, highlights the different treatment options available such as kinase inhibitors, chemotherapy, transplant and immunotherapeutic agents. He further talks about the difficulties of maintaining remission and how to overcome these issues. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Oliver Ottmann

3:38
Impact of increased drug availability on acute leukemia
Oliver Ottmann • 3 Jul 2020
3:24
Molecular profiling to determine treatment for ALL and AML
Oliver Ottmann • 3 Jul 2020
5:23
Treatment options for Ph+ ALL
Oliver Ottmann • 3 Jul 2020
15:02
The evolving landscape of ALL therapy and the impact of MRD
Dieter Hoelzer et al. • 17 May 2019

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals